Cerus (CERS) Receivables - Other (2018 - 2021)
Cerus (CERS) reported Receivables - Other of $2.7 million for Q3 2021, down 53.09% sequentially from $5.7 million in Q2 2021.
Cerus (CERS) Receivables - Other (2018 - 2021) Analysis & Trends
Cerus (CERS) has 3 years of Receivables - Other data on file, last reported at $2.7 million in Q3 2021.
- For the quarter ending Q3 2021, Receivables - Other changed N/A year-over-year to $2.7 million; the trailing twelve-month figure through Sep 2021 stood at $2.7 million (changed N/A YoY), and the FY2020 full-year result was $2.4 million, changed N/A from the prior year.
- Receivables - Other slipped to $2.7 million in Q3 2021, from $5.7 million in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $5.7 million in Q2 2021 to a low of $1.2 million in Q4 2018.
- A 3-year average of $3.0 million and a median of $2.7 million in 2021 frame the typical range for Receivables - Other.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.88 Bn | 176.59 Bn | 6.27 Bn |
| 2 | Stryker | 128.95 Bn | 126.07 Bn | 3.81 Bn |
| 3 | Medtronic | 108.68 Bn | 99.46 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.54 Bn | 67.09 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.26 Bn | 44.58 Bn | 1.29 Bn |
| 6 | Dexcom | 28.39 Bn | 27.28 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 28.22 Bn | 25.93 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.89 Bn | 26.31 Bn | - |
| 9 | Koninklijke Philips | 24.66 Bn | 21.54 Bn | 2.07 Bn |
| 10 | Cerus | 604.75 Mn | 524.33 Mn | 27.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 2.66 Mn |
| Sep 30, 2021 | 2.66 Mn |
| Jun 30, 2021 | 5.68 Mn |
| Jun 30, 2021 | 5.68 Mn |
| Mar 31, 2021 | 3.30 Mn |
| Mar 31, 2021 | 3.30 Mn |
| Dec 31, 2020 | 2.38 Mn |
| Dec 31, 2020 | 2.38 Mn |
| Dec 31, 2018 | 1.20 Mn |
| Dec 31, 2018 | 1.20 Mn |